RETRACTED: Amelioration of osteoporosis by menatetrenone in elderly female Parkinson’s disease patients with vitamin D deficiency

Satō, Yoshihiro; Honda, Yoshiyuki; Kaji, Masahide; Asoh, Takeshi; Hosokawa, Kanoko; Kondo, Izumi; Satoh, Kei

doi:10.1016/s8756-3282(02)00783-4

Cited by 69 publications

(51 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Similar results were obtained by menatetrenone therapy in Parkinson's disease patients [36], and the odds ratio of nonvertebral fractures in the untreated controls and the menatetrenone group was 11.5 [36].…”

Section: Discussionsupporting

confidence: 74%

Retraction : The Prevention of Hip Fracture with Menatetrenone and Risedronate Plus Calcium Supplementation in Elderly Patients with Alzheimer Disease: A Randomized Controlled Trial

et al. 2010

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 74%

Retraction : The Prevention of Hip Fracture with Menatetrenone and Risedronate Plus Calcium Supplementation in Elderly Patients with Alzheimer Disease: A Randomized Controlled Trial

et al. 2010

View full text Add to dashboard Cite

“…Recent clinical studies have suggested that MK-4 effectively prevents the occurrence of new frac tures in patients with postmenopausal osteoporosis (6 -8) and ameliorates osteoporosis associated with Parkin son's disease (9). The effects of MK-4 on bone metabo lism were demonstrated in a model of postmenopausal osteoporosis (10)(11)(12).…”

Section: Discussionmentioning

confidence: 99%

Menatetrenone Ameliorates Reduction in Bone Mineral Density and Bone Strength in Sciatic Neurectomized Rats

Iwasaki-Ishizuka

Yamato

Murayama

et al. 2003

Journal of Nutritional Science and Vitaminology, J Nutr Sci Vit

View full text Add to dashboard Cite

“…When vitamin D status is assessed as well as vitamin K, plasma 25(OH)D, phylloquinone and MK7 concentrations correlated with each other in elderly males 85 . In vitamin D deficiency 45mg/d MK4 can raise serum 1,25(OH)2D 86 and where 1,25(OH)2D is elevated MK4 can inhibit its induction of osteoclast formation 87 . Serum 1,25(OH)2D also correlates with serum OC in osteoporotic females 88 and Vitamin D supplementation can increase serum OC in postmenopausal women 89 and regulate its osteoblastic induction 16 , transcription and translation 83 , although there are mixed results in correlating serum ucOC concentration with 25(OH)D among elderly females 62,65 .…”

Section: Bonementioning

confidence: 99%

Cardiovascular Calcification and Bone: A Comparison of the Effects of Dietary and Serum Vitamin K and its Dependent Proteins

Nicoll¹,

Howard²,

Henein³

2015

ICFJ

View full text Add to dashboard Cite

This review compares the effect of vitamin K on cardiovascular (CV) calcification and bone health and shows that, in principal, the γ-carboxylation of the vitamin K-dependent proteins matrix Gla protein (MGP) and its bone equivalent osteocalcin (OC), generally ensures that hydroxyapatite is kept out of the CV system and is deposited in bone. This is an important finding, since there is currently no reliable treatment for CV calcification.Vitamin K2 (menaquinone) may be more effective in the arteries, while vitamin K1 (phylloquinone) is more active in bone. Nevertheless, there remains considerable uncertainty over the precise scope of the functions of MGP and OC, and their carboxylated and under-carboxylated forms, as well as the newly discovered vitamin K-dependent proteins. Although a diet high in vegetables could deliver adequate phylloquinone, supplementation of menaquinone may be necessary for those at risk of CV calcification. Several animal studies and one human study have demonstrated that arterial calcification could be reduced with vitamin K supplementation and there are further trials in progress. Patients on warfarin are particularly prone to CV calcification but there has been concern that supplementation would either counter warfarin treatment or destabilise INR. In fact, studies suggest that low dose phylloquinone did not increase coagulation and may improve the stability of anticoagulant therapy. Furthermore, use of oral anticoagulants which do not affect vitamin K metabolism, such as ximelagatran, could be used when there is a need for vitamin K supplementation for artery or bone health.

show abstract

RETRACTED: Amelioration of osteoporosis by menatetrenone in elderly female Parkinson’s disease patients with vitamin D deficiency

Cited by 69 publications

References 29 publications

Retraction : The Prevention of Hip Fracture with Menatetrenone and Risedronate Plus Calcium Supplementation in Elderly Patients with Alzheimer Disease: A Randomized Controlled Trial

Retraction : The Prevention of Hip Fracture with Menatetrenone and Risedronate Plus Calcium Supplementation in Elderly Patients with Alzheimer Disease: A Randomized Controlled Trial

Menatetrenone Ameliorates Reduction in Bone Mineral Density and Bone Strength in Sciatic Neurectomized Rats

Cardiovascular Calcification and Bone: A Comparison of the Effects of Dietary and Serum Vitamin K and its Dependent Proteins

Contact Info

Product

Resources

About